Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck

Elie El Rassy, Tarek Assi, Ziad Bakouny, Fadi El Karak, Nicholas Pavlidis, Marwan Ghosn

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    9 Citations (Scopus)

    Résumé

    Aim: The literature lacks direct evidence comparing the different regimens evaluated in the second-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Methods: We conducted a network meta-analysis (NMA) of the randomized controlled Phase III trials reporting on the second-line drug treatment options in R/M SCCHN. Results: The eligible trials included 11 regimens among which six targeted therapies, two immune checkpoint inhibitors and three chemotherapy regimens. Only nivolumab has shown statistically significant superiority over methotrexate in terms of overall survival (HR: 0.64; 95% CI: 0.43-0.96) and objective response rate (OR: 2.51; 95% CI: 1.07-5.86). Conclusion: Based on the efficacy and safety outcomes of this network meta-analysis, nivolumab seems the most favorable regimen inthe management of R/M SCCHN.

    langue originaleAnglais
    Pages (de - à)909-923
    Nombre de pages15
    journalFuture Oncology
    Volume15
    Numéro de publication8
    Les DOIs
    étatPublié - 1 mars 2019

    Contient cette citation